コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 of thrombosis if empirically administered an antifibrinolytic agent.
2 herefore, it has been proposed for use as an antifibrinolytic agent.
3 n those who received aminocaproic acid or no antifibrinolytic agent.
4 olism (VTE) risk cautions against the use of antifibrinolytic agents.
6 ared with the use of aminocaproic acid or no antifibrinolytic agent, aprotinin use was also associate
8 ich are representative of a class of in vivo antifibrinolytic agents, have been determined at 2.1 ang
10 by the SERPINE1 gene), a u-PA inhibitor and antifibrinolytic agent, is often elevated in obesity and
11 inogen to aid infectivity has suggested that antifibrinolytic agents may have antiviral benefits.
12 nephrotoxic insults are presented, including antifibrinolytic agents, obstructive jaundice, prostagla
13 and nonspecific support for hemostasis with antifibrinolytic agents or prothrombin complex concentra
14 teric inhibition of plasmin could led to new antifibrinolytic agent(s) that may exhibit better effica
16 d to delay clot lysis by enhancing a natural antifibrinolytic agent, thrombin-activatable fibrinolysi
17 or tranexamic acid, which have been used as antifibrinolytic agents to prevent blood loss during maj
18 from in vitro or animal studies, the use of antifibrinolytic agents to reduce bleeding in humans has